Meranti

• Research type

  Research Study

• Full title

  A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in the prevention of episodic or chronic migraine in adults

• IRAS ID

  1011914

• Contact name

  Alessandra Vella Valletta

• Contact email

  clinical.trials@ipsen.com

• Sponsor organisation

  Ipsen Innovation

• Clinicaltrials.gov Identifier

  NCT06625060

• Research summary

  A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers.

  Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. “Headache days” are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms.

  “Migraine days” occur when the headache displays clear migraine characteristics.

  This study aims to determine:
  • The safety and efficacy of injecting IPN10200 directly into the muscles of the head and neck to prevent EM and CM,
  • The right amount (dose) of IPN10200 to inject at each point,
  • The total amount (dose) of IPN10200 that provides the best balance between safety and efficacy preventing migraines.

  Participants will need to complete a daily electronic migraine diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.

  The study will consist of 3 periods:
  1. A ‘screening period’ to assess whether the participant can take part in the study.
  2. Step 1: The study will assess sequentially the safety of two doses of IPN10200,
  3. Step 2: New eligible participants will be divided into two groups based on their diagnosis (EM or CM). These groups will then be randomly assigned to one of three intervention groups: Dose A, Dose B or a placebo. The intervention will be given in a series of injections in muscles of the head, face and neck. Participants will be monitored for both efficacy and safety until they complete the Week 36 visit (the end of study).

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  25/SC/0254

• Date of REC Opinion

  16 Sep 2025

• REC opinion

  Further Information Favourable Opinion